Page 15 - புற்றுநோய் ஆராய்ச்சி இங்கிலாந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cancer Research UK teams up with Teon on new cancer drug 2nd March 2021 The focus of the agreement is Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist, TT-702. Under the terms of the agreement, CRUK will sponsor the first-in-human Phase I/II clinical development of TT-702. This will be led by a team at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust. The Centre for Drug Development, Teon and a team of clinical investigators led by professor Johann de Bono are currently preparing to launch the early clinical trial in the second half of 2021.

United kingdomCity ofNigel blackburnInstitute of cancer researchCancer research united kingdomCentre for drug developmentTeon therapeuticsCancer researchRoyal marsdenDrug developmentJohann de bonoCancer research ukResearch agreementஒன்றுபட்டது கிஂக்டம்நகரம் ஆஃப்நைகல் கருப்பட்டி